Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Tobacco Smoke Exposure Limits the Therapeutic Benefit of Tezacaftor-Ivacaftor in Pediatric Patients with Cystic Fibrosis.

Tobacco Smoke Exposure Limits the Therapeutic Benefit of Tezacaftor-Ivacaftor in Pediatric Patients with Cystic Fibrosis.

Resource Type

CF Research News

Authors

Elizabeth Baker, William T Harris, Steven M Rowe, Sarah B Rutland, Gabriela R Oates

References

J Cyst Fibros. 2021 Jul;20(4):612-617. doi: 10.1016/j.jcf.2020.09.011. Epub 2020 Oct 3.

Document

PDF icon Baker 2020_FINAL.pdf [1]

Link

Scientific Abstract [2]

Theme

Care of patients with CF [3]
Pulmonology [4]

Date

Tuesday, July 20, 2021

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [5]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/tobacco-smoke-exposure-limits-therapeutic-benefit-tezacaftor

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/Baker%202020_FINAL.pdf [2] https://pubmed.ncbi.nlm.nih.gov/33023836/ [3] https://www.ecfs.eu/research-article-themes/care-patients-cf [4] https://www.ecfs.eu/research-article-themes/pulmonology [5] https://www.ecfs.eu/resource-guideline-type/other-guidelines